

Inside this Newsletter:

- Liquid Biopsy: The Revolutionary Aspect of Molecular Oncology
- Skin Biopsy: Lesions and Inflammation
- Updates From The Lab

## Introducing Liquid Biopsy: The Revolutionary Aspect of Molecular Oncology

**Dr Mirette Saad**



Cancer, a leading cause of mortality, is associated with mutated genes. Analysis of tumour associated genetic alterations is increasingly used for diagnostic, prognostic and treatment purposes. Precision or personalised medicine harnesses genomic knowledge banks to tailor individualised treatments based on patients' or their tumours' genetic signatures.


## Somatic Mutations in Cancer

A high-quality genomic analysis is critical for personalised pharmacotherapy in patients with cancer. Identifying activated therapeutic gene targets (e.g., *BRAF* in melanoma, *EGFR* in lung cancer and *KRAS* in colorectal cancer) with established cancer associations, using focused panels for targeted cancer sequencing, allows for deeper coverage of those genes and higher sensitivity to confidently call rare variants (e.g., *PTEN* and *KIT*) in rare tumour subclones, including FFPE tissue. The advent of therapies targeting genomic alterations has improved the care of patients with certain types of cancer dramatically. Thus, elucidating the genetic profile of a given tumour is potentially useful in designing tailored treatment regimens that avoid unnecessary toxic therapy.

## Liquid Biopsy

The genetic profile of solid tumours is currently obtained from surgical or biopsy specimens; however, performing biopsies, particularly in lung cancer, is not always possible in advanced disease stages and is associated with potential complications. Also, information acquired from a single biopsy provides a limited snap-shot of a tumour and might fail to reflect its true genetic and cellular heterogeneity.

While molecular targets were initially detected in nucleic acid samples extracted from tumour solid tissues, detection of circulating nucleic acids in blood has enabled the development of what has become known as “liquid biopsy”.



Certain fragments of DNA, cell-free DNA (cfDNA), have been shown to be elevated in the plasma of patients with cancer. This increase is the result of the rapid turnover of cells within the tumour, releasing DNA into the circulation<sup>1</sup> (see Fig. 1). With new highly sensitive technologies, cell-free circulating DNA can now be isolated and analysed. cfDNA analysis can complement and in many instances correlate to solid tissue biopsies<sup>3,4</sup> for real-time molecular monitoring of treatment, detection of recurrence, and tracking resistance. Circulating tumour DNA (ctDNA) reflects the overall tumour information and is not biased by analysing only a small fraction of the tumour. It is always accessible, in contrast to the lung cancer tissue.

Various studies in breast, lung and colorectal cancers have demonstrated the potential application of ctDNA analysis at each stage of clinical management: early diagnosis<sup>12,13</sup>, molecular

profiling<sup>14</sup>, prognostication<sup>12,15,16</sup>, detection of residual disease<sup>7,17</sup>, monitoring response and clonal evolution<sup>18,19,20</sup>. Lastly, there have been recent approvals by the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) for detection of the tyrosine kinase resistant clone *EGFR* p.T790M mutation in plasma as a companion diagnostic for second-line treatment of metastatic *EGFR*-mutant non-small cell lung cancer (NSCLC)<sup>21,25</sup>.

Prospective research cohort studies are ongoing to explore the possible clinical applications of ctDNA in cancer. The inclusion of ctDNA analysis into multiple clinical trials (ClinicalTrials.gov), signals the recent integration of this form of biomarker into routine clinical oncology.

## Implementation of Aspect Liquid Biopsy

Clinical Labs has analytically validated an integrated test process for a comprehensive mutation profiling assay for clinical oncology patients using circulating tumour derived DNA extracted from blood.

Our technology, including (NGS), MassArray Agena Biosciences ULTRAseek and Droplet Digital PCR (ddPCR), is able to identify clinically relevant variants at a sensitivity down to 0.5% or less.

## Aspect Liquid Biopsy is Less Invasive

Surgical tissue biopsies have some inherent shortcomings and risks, and do not guarantee enough material will be collected for accurate analysis in clinical practice. Liquid biopsy provides a non-invasive alternative sample source, allowing the identification of genomic alterations that can be addressed by targeted therapy. This non-invasive type of liquid biopsy can be taken easily and repeatedly over the course of a patient's treatment. ctDNA provides new insight into diagnosis, prognosis and patient follow-up compared to traditional tissue biopsy.

## The Quality Choice for Cancer Treatment Response Monitoring

Early detection is the holy grail of cancer management. The biggest advantage of liquid biopsy is the ability to detect the cancer biomarkers in blood earlier than conventional methods<sup>22,23</sup>. While correlating with imaging scans, it has been demonstrated that monitoring for tumour-derived DNA in the plasma can identify relapse or drug resistance well before clinical signs and symptoms appear, enabling earlier intervention and better outcomes<sup>22,23</sup>.

In the future, instead of extensive imaging and invasive tissue biopsies, employing ctDNA as liquid biopsies could be used to guide cancer treatment decisions and perhaps even screen for tumours that are not yet visible on imaging.

Over the past several years there have been multiple studies demonstrating the clinical utility of liquid biopsy ctDNA analysis following surgical resection of colorectal cancers (CRCs)<sup>7</sup>. Most studies demonstrate better outcomes when no tumour-derived DNA is found in patients following surgery, or chemotherapy in colorectal cancer patients<sup>7</sup>, whereas those where tumour DNA

is still present do better with the addition of more aggressive targeted treatment or chemotherapy.

It is important to note that for melanoma patients who harbour a *BRAF* mutation, targeted therapy remains the first-line treatment, particularly in Australia<sup>11</sup>. Tracking of *BRAF*V600 ctDNA levels as patients undergo targeted treatment can potentially help identify the period when resistance to targeted therapy emerges. Gray et al. and Lee et al.<sup>22,24</sup> showed that baseline ctDNA levels predict response to immunotherapy in melanoma patients, and low basal ctDNA levels were significantly associated with long-term clinical benefit. Nevertheless, prospective clinical studies of survival in a larger cohort of patients are underway to validate the predictive value of ctDNA in melanoma patients treated with immunotherapy.

### Aspect Liquid Biopsy Can Guide Treatment Decisions

Liquid biopsy can offer valuable insights into how best to treat cancer. ctDNA can be used to monitor the effects of cancer treatment and give an early warning about possible recurrence. The detection of resistant clones can offer clues to the reasons for treatment resistance<sup>5,6</sup> (see Fig.2). Recently, a third-generation *EGFR* Tyrosine Kinase Inhibitor (*TKI*), which is effective in tumours harbouring the T790M *EGFR* mutation (~50-60% of lung cancer patients<sup>5,6,10</sup>), was approved in Australia for patients with NSCLC harbouring the *EGFR* T790M mutation following progression on an *EGFR TKI*<sup>9</sup>.

Serial analysis of ctDNA from the time of diagnosis throughout treatment can provide a dynamic picture of molecular disease changes, providing evidence that this non-invasive approach could also be used to monitor the development of secondary resistance and identify heterogeneous sub-clonal populations of tumour cells developing during the course of treatment. NCCN guidelines<sup>8</sup> recommend the use of liquid biopsy for lung cancer patients as an alternative for tissue in initial T790M *EGFR* testing<sup>2,6</sup>. However, if the plasma is negative, then a tissue biopsy is recommended, if feasible.

## Tumour Progression




Fig 2.

### How to Order?

Health Practitioners can order Aspect Liquid Biopsy for cancer patients using the Aspect request form. Some required information is listed on the form, including type of cancer and whether it is a new diagnosis and if the patient is on anti-tumour therapy (if known). Health Practitioners can download the Aspect Liquid Biopsy form on the Clinical Labs website at [clinicallabs.com.au/aspect](http://clinicallabs.com.au/aspect)

### What is the cost?

Out-of-pocket fee of \$550. (No Medicare rebate available)

### When will results be available?

Results will be available after 5-7 business days from the sample receipt date.

### How is it collected?

This test requires two 10ml blood samples which can be taken at any of our collection centres.

## References

- Fleischhacker M et al., (2007) *Biochem Biophys Acta* 1775:181-232.
- John T et al., (2017) *Asia-Pacific J of Clin Oncol* 13:296-303.
- Thierry A et al., (2014) *Nat Med* 20:430-435.
- Newman A. M et al., (2014) *Nat Med* 20 (5):548-554.
- Thress K et al., (2015) *Lung Cancer* 90:509-515.
- Wu Y et al., (2017) *Br J cancer* 116:175-185.
- Tie J et al., (2016) *Sci Transl Med* 8:346ra92.
- National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Non-small cell lung cancer (7 April 2017)
- AstraZeneca. TAGRISSO (osimertinib mesilate) product information; 2016.
- Yu H et al., (2013) *Clin Cancer Res* 19:2240-2247.
- Spagnolo F et al., (2015) *Onco Targets Ther* 8:157-168.
- Bettegowda C et al., (2014) *Sci Transl Med* 6:224ra24.
- Haselmann V et al., (2018) *Clinical Chemistry* 64 (5):830-842
- Murtaza M et al., (2015) *Nat Commun* 6:8760.
- Dawson S et al., (2013) *N Engl J Med* 368 (13):1199-1209.
- Forshev T et al., (2012) *Sci Transl Med* 4 (136):136ra68-136ra68.
- Garcia-Murillas I et al., (2015) *Sci Transl Med* 7 (302):302ra133-302ra133.
- Murtaza M et al., (2013) *Nature* 497 (7447):108-112.
- Wang W et al., (2017) *Cancer Med* 6 (1):154-162.
- Van Emburgh B et al., (2014) *Mol Oncol* 8 (6):1084-1094.
- Premarket approval P150044 d Cobas *EGFR* MUTATION TEST V2. Cited 2016; Available from: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P150044>
- Gray E et al., (2015) *Oncotarget* 6 (39):42008-42018.
- Girotti M et al., (2016) *Cancer Discov* 6 (3):286-299.
- Lee J et al., (2017), *Ann Oncol*.
- Calapre L et al., (2017) *Cancer Letters* 404:62-69.

# About the author: Dr Mirette Saad

**Precision Medicine, Cancer Genetics,  
Antenatal Screening, NIPT, Endocrine,  
Fertility Testing and Research  
& Medical Teaching**

Dr Mirette Saad is a Consultant Chemical Pathologist and the National Clinical Director of Molecular Genetic Pathology at Australian Clinical Labs. At Clinical Labs, Dr Mirette Saad leads the Molecular Genetic testing for Non-Invasive Prenatal Testing (NIPT), carrier screening, personalised drug therapy and cancer. She is a member of the RCPA Chemical Pathology Advisory Committee and a Chair of precision medicine services at Australian Clinical Labs.

**Chemical  
Pathologist**

**Molecular  
Genetic  
Pathologist**

## Dr Mirette Saad

*National Clinical Director of  
Molecular Pathology*

*MBBS (HONS), MD (HONS),  
MAACB, FRCPA, PHD*

Email: mirette.saad@  
clinicallabs.com.au  
Phone: (03) 9538 6762  
Location: Clayton, Victoria



**harmony**<sup>®</sup>  
PRENATAL TEST  
*performed in Australia*

## Pregnancy screening for chromosomal abnormalities



### Harmony fits any practice

To learn more about Harmony, please visit [clinicallabs.com.au/harmony](http://clinicallabs.com.au/harmony), call 1300 750 610 or email [harmony@clinicallabs.com.au](mailto:harmony@clinicallabs.com.au).

Non-invasive prenatal testing (NIPT) based on cell-free DNA analysis is not diagnostic; results should be confirmed by diagnostic testing. Before making any treatment decisions, all women should discuss their results with their healthcare provider, who can recommend confirmatory, diagnostic testing where appropriate. The Harmony Prenatal Test was developed by Ariosa Diagnostics. The Harmony Prenatal Test is performed in Australia. HARMONY PRENATAL TEST and HARMONY are trademarks of Roche. All other trademarks are the property of their respective owners.

1. Norton et al. N Engl J Med. 2015 Apr 23;372(17):1589-97.  
2. Norton et al. Am J Obstet Gynecol. 2012 Aug;207(2):137.e1-8.  
3. Verweij et al. Prenat Diagn. 2013 Oct;33(10):996-1001.

4. Nicolaides et al. Am J Obstet Gynecol. 2012 Nov;207(5):374.e1-6.  
5. Gil et al. Fetal Diagn Ther. 2014;35:204-11  
6. Data on file, Roche

**Patients are asking — and  
clinicians need to be equipped  
with the right knowledge.**


Harmony<sup>®</sup> is the most broadly studied non-invasive prenatal test (NIPT) for Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), and Patau syndrome (trisomy 13).<sup>1-5</sup> The Harmony Prenatal Test uses a proprietary, targeted DNA-based technology to provide you and your patients a greater level of assurance—simply requiring a maternal blood sample.

**Harmony can be ordered for  
expectant mothers as early as  
10 weeks<sup>1</sup>.**

While traditional screening can miss as many as 15% of pregnancies with trisomy 21, Harmony's DNA-based technology accurately identifies more than 99% of cases.<sup>1</sup> Clinicians in more than 100 countries have trusted Harmony.<sup>6</sup>

# Skin Biopsy: Lesions and Inflammation

Dr Jenny Grew



Biopsies of the skin are generally used to diagnose skin pathologies, but occasionally are used in treatment. This information sheet serves to outline the techniques of biopsy, including: excision (elliptical, saucerisation/shave, punch), incision, superficial shave, punch and wedge. The type of biopsy a clinician uses is dependent on the pathology of the individual patient.

complete removal of in situ/thin lesions. The margins of these samples must remain intact and flat, enabling assessment of the entire sample (achieved by flattening the sample on a card). If atypical/pigmented areas are seen at the base following saucerisation, punch or elliptical excision of the base area may be required to remove further pathology.

Punch biopsy is preferable to shave biopsies, which are prone to sample errors. Many clinicians prefer to use a punch biopsy technique for thick, keratotic lesions. Large, deep lesions require an incisional or wedge biopsy, which includes tumor/fat margins, for accurate diagnosis.

## Non-Pigmented Discrete Lesions



- A biopsy should be performed when a diagnosis is uncertain.
- Complete excision is recommended for suspected malignancy.
- Small and/or non-suspicious lesions can be removed using punch or shave biopsy.

Excision Biopsy: A well-differentiated squamous cell carcinoma or keratoacanthomas is diagnosed by excising the entire lesion. Partial biopsy often does not present enough information to make an accurate diagnosis.

For a patient with a broad lesion who is prone to keloid/hypertrophic scar formation, saucerisation could aid in negating surgical and/or cosmetic difficulties, and can be used for the

## Pigmented Lesions



Suspected melanoma:

- Excision margins 1-3 mm
- Small or superficial biopsies may not be representative - subsequent tumor staging may be difficult.

Partial biopsies can be used:

- If melanoma is unlikely
- For benign, pigmented melanotic macules on the genitals
- Cosmetic concerns
- Broad lesions
- Surgically difficult sites

Saucerisation (including a 0.5-1.0 mm margin) can be performed for 'ugly duckling' dysplastic naevi.

If partial biopsy of suspected melanoma is unavoidable:

- The thickest area/s should be biopsied at greater depth.
- Multiple small shaves across different areas of lentigo-maligna-type lesions are recommended.

Small suspicious acral lesions can be removed using saucerisation which include a margin of healthy skin.

**Annular lesions (e.g. porokeratosis):** Incisional biopsies should be taken from the center of the lesion in an outwards direction and include a 1 mm margin of normal skin.

**Lupus erythematosus, dermatomyositis and vasculitis:** The biopsy site is crucial. For lupus and dermatomyositis, biopsy an established lesion (>6 months old) that is active for routine histology and DIF. For vasculitis, biopsy an established, purpuric lesion (>72 hours old) for routine histology and an acute lesion (<24 hours old) for DIF.

**Panniculitis:** A deep or incisional biopsy, including subcutaneous fat, is recommended. If necrosis is present, a sample should be sent for culture.

### Rashes/Inflammatory Conditions



- 4 mm punch biopsy
- Incisional biopsy for larger, deeper lesions
- Saucerisation to remove entire blisters

Many rashes have similar histological patterns. A clinical description of the rash should accompany the biopsy sample and include: distribution, duration and course, other history (e.g. medication), clinical photographs (sent via email or text message) and clinical diagnosis to ensure accurate categorization of the sample.

Stating the biopsy type and reason for the biopsy will ensure that the sample is handled appropriately.

**Lesions:** A small rim of perilesional skin should be included in a biopsy of tissue that has not been excoriated or ulcerated. Frictional sites and lower limbs may have secondary features resulting in false negative results, and biopsy of these areas should be avoided. Multiple biopsies of the rash and a concurrent biopsy of normal skin may be helpful in disorders that are of polymorphous and pigmented appearance, respectively.

**Blisters:** Biopsies maintaining the attachment of the blister roof are important. A second biopsy of a non-blistered lesion or normal skin immediately adjacent to the lesion should be taken for direct immunofluorescence microscopy (DIF) and preserved in immunofluorescence transport medium or phosphate buffer saline.

### Alopecia



- Two punch biopsies
- 4 mm diameter
- Parallel to the direction of hair growth/emergence.

**Alopecia:** Two biopsies should include the entire follicular unit, subcutaneous fat and be at least 5-6 mm in depth (no hairs emerging from the deep aspect). Such biopsies will allow the pathological examination of both vertical and horizontal sections of the biopsy. Clinical information including area of scalp involved, race, duration and clinical differential diagnosis are important.

#### Biopsy site

- **Non-cicatricial alopecia:** Most prominent area of hair loss.
- **Cicatricial alopecia:** Area of hair loss but not completely bald (active area where at least 6 months duration). Dermoscopy help identify suitable biopsy sites, e.g. areas of scaling or abnormal pigmentation. A second biopsy from the same area can be sent for DIF.

- Dr Jenny Grew

# About the author: Dr Jenny Grew

**Breast, Gastrointestinal, Molecular Pathology, Cytology,  
Gynaecological & Cutaneous Pathology**

Dr Jenny Grew joined our team at Australian Clinical Labs as Clinical Director Anatomical Pathology for WA in 2017. A graduate of the University of Otago (MBChB, 1992) Jenny began pathology training at Christchurch Hospital (NZ), gaining RCPA Fellowship in 2001.

Jenny moved from New Zealand with her family (husband Keith and son Dominic) to Queensland in 2007, taking up the role of Pathologist in charge, providing service to 6 public and private hospitals.



**Anatomical  
Pathologist**

**Dr Jenny Grew**

*MBChB, FRCPA, AFRACMA*

Email: [jenny.grew@clinallabs.com.au](mailto:jenny.grew@clinallabs.com.au)

Phone: 1300 367 674

Location: Subiaco, Western Australia

AUSTRALIAN  
**Clinicalabs**

## Join our Skin Excision Evaluation Program

Australian Clinical Labs' unique program combines the latest scientific and technological advancements to help deliver better diagnostic outcomes for both doctors and patients. Taking part is easy and you may qualify for Continuing Professional Development (CPD) points.

Our Skin Excision Evaluation Program enables general practitioners who refer skin pathology to Australian Clinical Labs to submit their provisional diagnosis on cases in which histological evaluation is needed. Monthly Skin Excision Evaluation Reports will be generated for all participants, highlighting performance against the performance of peers, while maintaining confidentiality of all clinics.

**Sign up today!**

**1300 134 111**

**[clinallabs.com.au/skin](http://clinallabs.com.au/skin)**

*Earn  
CPD points*





# Subscribe to our electronic mailing list

Subscribe to the Clinical Labs mailing list and receive our bi-monthly clinical newsletter, important updates, educational resources and more delivered directly to your inbox, simply visit [clinicallabs.com.au/subscribe](http://clinicallabs.com.au/subscribe) and follow the instructions.

Alternatively, complete the form below, tear along the perforated edge and fax it to Clinical Labs Head Office on **(03) 9538 6733**

Title

Given Name

Surname

Email

Practice Name

Practice Address

Practice Suburb

Post Code

Please tick one of the below:

- General Practitioner
- Specialist
- Medical Centre / Practice Manager

**Thank you**

# Updates From The Lab

## Australian Clinical Labs offers South Australia the most technologically advanced pathology laboratory in the state.

Clinical Labs is pleased to announce it will relocate its main laboratory operations into the State's most technologically advanced laboratory in early 2019.

The 2,500 square metre facility will be located very close to the Adelaide Airport business park. It will operate as a national centre of excellence and referral laboratory within Clinical Labs' network of specialist laboratories in Australia. Being so close to the airport guarantees swift access and connection to other specialist labs when required.

The stunning new lab will feature world-class pathology technology and logistics equipment to greatly improve work practice efficiencies. It will also boast modern staff accommodation, warehousing and 133 car parks for staff and visitors.

Clinical Labs Group CEO and Managing Director, Melinda McGrath said, "I am thrilled to share this news today. This significant investment demonstrates our Board's long-term commitment to the South Australian community.

"This is a designed-for-purpose facility offering the most technologically advanced diagnostic services in biochemistry, haematology, histopathology, cytology, microbiology and immunology, genetics/molecular biology, and toxicology specialities," Ms McGrath said.

South Australian State Manager Eric Swain stated "this business has provided high quality pathology services to South Australian doctors and their patients since 1936. This is a clear demonstration of Clinical Labs' commitment to our medical community and their patients. It will be a terrific facility for our clients and our staff," he said.

The property owner, Barwon Partners' Tom Patrick added: "This project represents a strong investment opportunity for our clients and positions Barwon as a reliable real estate capital partner to its important tenant partners," he said.

Managing Director of Adelaide-based Leyton Property, Hamish Brown commented: "We are excited to help deliver this critical piece of healthcare infrastructure. As a local developer, we think it's a great result for our state and particularly for the Airport precinct," he said.



To receive our bi-monthly clinical newsletter, updates, educational resources and more, go to [clinicallabs.com.au/subscribe](https://www.clinicallabs.com.au/subscribe) and follow the instructions.

AUSTRALIAN  
**Clinicallabs**